Immunovant, Inc.
IMVTImmunovant is a clinical-stage biotechnology company focused on developing innovative therapies for autoimmune diseases driven by pathogenic immunoglobulin G (IgG) antibodies.
Earnings
Next report
Aug 10, 2026 (In 4 weeks)Financials
Q4 2026Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Immunovant is a clinical-stage biotechnology company focused on developing innovative therapies for autoimmune diseases driven by pathogenic immunoglobulin G (IgG) antibodies. The company's core value proposition centers on its neonatal fragment crystallizable receptor (FcRn) inhibitors, which are designed to reduce harmful antibody levels while maintaining a favorable safety profile. Their lead candidate aims to provide best-in-class efficacy through deep IgG reduction and convenient subcutaneous self-administration.
Immunovant is a clinical-stage developer positioning its lead candidate as a potential best-in-class FcRn inhibitor with superior IgG reduction and safety compared to existing competitors.
Questions, answered.
- What is Immunovant, Inc.'s market cap?
- Immunovant, Inc. (IMVT) has a market capitalization of $8.4B and trades on NASDAQ.
- Who are Immunovant, Inc.'s competitors?
- Immunovant, Inc.'s key competitors include Argenx SE, UCB S.A., Johnson & Johnson, and others. These companies compete in similar markets and product categories.
- Who does Immunovant, Inc. partner with?
- Immunovant, Inc.'s notable partners include Ypsomed AG, HanAll Biopharma, Roivant Sciences.
- Where is Immunovant, Inc. headquartered?
- Immunovant, Inc. is headquartered in United States of America and employs approximately 207 people. It has been publicly traded since 2019.